Table 3.
Univariable and multivariable analyses in secondary cohort (n = 191). PR, progesterone receptor; Z‐4OHtam, Z‐4‐hydroxy‐tamoxifen.
| Factor | Event/patients | Survival % | HR (95% CI) | P (Cox) |
|---|---|---|---|---|
| Age (linear) | – | 0.95 (0.87–1.03) | 0.198 | |
| pT | ||||
| pT1 | 9/96 | 90.6% | 1 | |
| pT2 | 16/95 | 83.2% | 1.89 (0.84–4.28) | 0.127 |
| pN | ||||
| Neg | 5/76 | 93.4% | 1 | |
| Pos | 20/115 | 82.6% | 2.77 (1.04–7.38) | 0.042 |
| Pos a | 3.06 (1.14–8.19) | 0.026 a | ||
| Grade | ||||
| Grades 1&2 | 15/125 | 88.0% | 1 | |
| Grade 3 | 10/64 | 84.4% | 1.33 (0.60–2.97) | 0.480 |
| HER2 | ||||
| Neg | 13/113 | 88.5% | 1 | |
| Pos | 2/15 | 86.7% | 1.20 (0.27–5.31) | 0.813 |
| PR | ||||
| Pos | 19/165 | 88.5% | 1 | |
| Neg | 6/24 | 75.0% | 2.69 (1.07–6.73) | 0.035 |
| Z–Endoxifen | ||||
| > 9 nm | 23/174 | 87.5% | 1 | |
| ≤ 9 nm | 2/16 | 86.8% | 0.98 (0.23–4.15) | 0.976 |
| Z4OHtam | ||||
| > 3.26 nm | 17/156 | 89.1% | 1 | |
| ≤ 3.26 nm | 8/35 | 77.1% | 2.37 (1.02–5.48) | 0.045 |
| ≤ 3.26 nm a | 2.71 (1.15–6.25) | 0.022 a | ||
a
Multivariable analyses with clinically relevant variables or variables with P‐value < 0.2 from the univariate analysis, that is, Z‐4OHtam, PR, age, pT, and pN in the model).